The BGMA represents the interests of UK based manufacturers and suppliers of generic medicines and promotes the development of the generic medicines industry in the United Kingdom.
We represent the views and interests of our members and industry generally to the UK government, the devolved administrations, regulators, other relevant third parties, including where appropriate the institutions of the European Union.
The BGMA is made up of members of the generic manufacturing industry, who between them account for more than 90% of the total UK market by volume.
A key feature of the strong generics industry in the UK is that it introduces competition to the supply of prescription medicines making drugs more affordable to the NHS and enhancing their availability to patients.
According to the most recent NHS figures nearly 650million items are prescribed generically every year. The increase of generic prescriptions, allied with a reduction in the net ingredients costs, means that overall savings to the NHS medicines bill have now passed more than £10.25billion annually.